Micron expects fiscal Q1 revenue of $61.5B ±$1.5B as it raises fiscal 2027 CapEx plans amid tighter 2027-2028 supply-demand (NASDAQ:MU)October 1, 2026
Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs Markets July 20, 2022 NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. at this time introduced it has entered…
